Haisco Pharmaceutical Group revenue and financials
¥62.18Change from previous close: +0.40%Absolute change: +¥0.25
In the fiscal year ended December 2025, Haisco Pharmaceutical Group reported revenue of ¥4.39B (+17.91% year over year). Net income was ¥259.58M, a net margin of 5.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +17.91%
- 2025 vs 2024
- Net income growth
- −34.36%
- 2025 vs 2024
- Net margin
- 5.9%
- 2024: 10.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Capital expenditure | -81.7 | -68.7 | -59.8 | -105 | -94.3 |
| Investing cash flow | -66.6 | -198 | -48.5 | -96.4 | 59.4 |
| Financing cash flow | -298 | 280 | -363 | -75.5 | 165 |
| Dividends paid | -306 | -6.2 | -6.8 | -159 | -160 |
| Debt issued | 290 | 500 | 0.0 | 500 | 482 |
| Debt repaid | -281 | -215 | -356 | -416 | -161 |
| Effect of exchange rates | -10.4 | -6.7 | -3.5 | -0.7 | -0.5 |
| Net change in cash | 47.0 | 431 | -14.9 | 159 | 243 |
| Free cash flow | 330 | 280 | 337 | 226 | -76.0 |